Clinical Efficacy of Ubiquitous Healthcare System for Elderly Patients With Type 2 Diabetes Mellitus
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diabetes
- Sponsor
- Seoul National University Bundang Hospital
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Target goal of HbA1c (< 7.0%) without hypoglycemia
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Ubiquitous healthcare service for elderly patients with type 2 diabetes provides real-time glycemic monitoring and glucose control implemented by clinical decision support system (CDSS) using wire and wireless communication and information technology.
To evaluate the clinical efficacy of this system, researchers plan to compare the improvement of glycemic control, self-management, and quality of life among three study groups: control, self glucose monitoring, and U-healthcare group.
Detailed Description
Recently, the application of internet-based glucose control system showed better long term glucose control compared to the conventional treatment. This study has become the foundation of web-based methodology in the glucose control. In addition, the combined application of mobile device and web-based monitoring system for chronic diseases showed improvement in various metabolic parameters in obese patients with diabetes and hypertension. Thus, the application of U-healthcare based on advanced information technology would be helpful in the diabetes management. We plan to provide an individualized U-healthcare service using advanced information technology that enables more effective glucose control.
Investigators
Soo Lim
Professor
Seoul National University Bundang Hospital
Eligibility Criteria
Inclusion Criteria
- •Type 2 diabetes
- •age: 60 \~ 85 yrs
- •HbA1c: 6.5%-11.0%
- •duration of diabetes: less than 30 years
- •BMI: 20-35
Exclusion Criteria
- •systemic corticosteroid administered within previous 6 months
- •history of myocardial ischemia
- •Heart failure, NYHA Class II-IV
- •Thyroid disease with abnormal TFT
- •Anti-obesity drugs or slimming products within previous 3 months
Outcomes
Primary Outcomes
Target goal of HbA1c (< 7.0%) without hypoglycemia
Time Frame: 24 weeks
Percent of patients who reach target goal of HbA1c (\< 7.0%) without hypoglycemia
Secondary Outcomes
- quality of life(24 weeks)
- amount of exercise(24 weeks)
- Body mass index (BMI) changes(Body mass index)